"People who replaced a protease inhibitor (PI) with raltegravir did as well if they took standard twice-daily raltegravir or if they later switched to once-daily raltegravir in a 125-person study [1]. Clinicians at Carlos III Hospital in Madrid saw a trend toward improved quality of life in the once-daily group."
Read more in NATAP, September 15, 2009.
Note: This was not a randomized trial.
0 comments:
Post a Comment